FDA still skeptical of ALS drug ahead of high-stakes meeting

Holly Fernandez-Lynch of the Perelman School of Medicine says that Canadian regulators’ decision to approve Amylyx’s ALS drug puts FDA regulators in a precarious position.

・ From Associated Press